ADIHEX
18.5.2020 22:50:10 CEST | Business Wire | Press release
The Higher Organizing Committee of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) has announced that the 18th edition of the exhibition, which was scheduled for 29th September - 3rd October 2020, will be rescheduled to September 2021, under the theme of ‘Sustainability and Heritage… A Reborn Aspiration’.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200518005737/en/
The 18th edition of ADIHEX will be organised by the Emirates Falconers’ Club at the Abu Dhabi National Exhibition Centre (ADNEC), under the patronage of HH Sheikh Hamdan bin Zayed Al Nahyan, Ruler's Representative in Al Dhafra Region and Chairman of Emirates Falconers’ Club.
The decision to postpone the exhibition for a year was taken in consideration due to the COVID-19 pandemic outbreak, to ensure the health and safety of all participants and visitors.
H.E. Majid Ali Al Mansouri, Chairman of the Higher Organizing Committee of the exhibition has revealed major changes for exhibitors and visitors including enhancing the quality of its exhibits, products, and unique innovations from the world of hunting and equestrian; maintaining ADIHEX’s profile as the largest annual event of its kind in the Middle East and Africa.
The comprehensive expansion plan also includes improving the content of the event by providing innovative services, technologies, activities, and events with a renewed vision, strengthening the exhibition’s role in preserving the UAE’s heritage and promoting sustainable hunting. This is in addition to organizing more environmental, heritage, art, educational and awareness-raising activities.
ADIHEX continues in its effort to achieve its mission by developing long-term plans in line with the national strategy of celebrating UAE’s five decades of achievements in 2021 and preparing for the coming 50 years with an ambitious vision which looks towards the future. This combined with a commitment to excellence and competitiveness will align the exhibition with the governments directives to enter the new phase with determination and persistence.
As the number of exhibitors has multiplied more than 16 times over the past editions, ADIHEX 2019 hosted more than 650 companies and brands from 41 countries in an exhibition area of 45,000 square meters.
ADIHEX also enjoys great popularity around the world and is awaited by many - individuals and families- year after year, as a record of more than 1,500,000 people visited the exhibition over the past 17 editions.
ADIHEX is a non-profit event initiated in Abu Dhabi by the UAE's Founding Father, the late Sheikh Zayed bin Sultan Al Nahyan who honoured the first edition in 2003 by visiting the event. Since its inauguration, ADIHEX has become a benchmark for B2B and B2C events and one of the key events organized within the UAE.
ADIHEX provides its participants and visitors with a comprehensive offering within its 11 sectors which are: veterinary products and services, hunting guns, media, outdoor leisure vehicles and equipment, hunting tourism and safari, arts and crafts, equestrian, falconry, fishing and marine sports, hunting and camping equipment and finally cultural heritage.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005737/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom